MGFA has partnered with Bionews to feature the “Myasthenia Gravis News” feed on our MGFA website. We are excited to offer the MG Community this insightful and informative news feed that covers many aspects of living with myasthenia – from research and study results to managing MG, helpful tips, and important news from across the MG World.
Myasthenia Gravis News is a digital platform intended to provide the myasthenia gravis (MG) community with the most recent news and information on MG, as well as first-hand community perspectives from patient and caregiver columnists. All articles on Myasthenia Gravis News are original content produced by in-house writers and editors. Occasionally, BioNews seeks the opinion of outside experts for interviews and Q&As.
Myasthenia Gravis News – The Web’s Daily Resource for Myasthenia Gravis News
- Realizing my healthy loved ones are dealing with survivor’s guilt
by Sarah Bendiff on November 6, 2025 at 3:00 pmDepending on the kind of person you are, you might react differently to the idea of being responsible for someone who needs help. Recently, I was watching a YouTube video The post Realizing my healthy loved ones are dealing with survivor’s guilt appeared first on Myasthenia Gravis News.
- Scholarship success stories inspire new round of MG applications
by Margarida Maia, PhD on November 6, 2025 at 1:45 pmFifteen college or trade school scholarships are now available for people with myasthenia gravis (MG) and their immediate family members through the second annual UCB U.S. Myasthenia Gravis Scholarship program. The post Scholarship success stories inspire new round of MG applications appeared first on Myasthenia Gravis News.
- MGFA Session 2025: Single dose of KYV-101 eases gMG symptoms
by Lila Levinson, PhD on November 5, 2025 at 1:15 pmA single dose of KYV-101, a cell therapy being developed by Kyverna Therapeutics for generalized myasthenia gravis (gMG), led to rapid and sustained reductions in symptom severity — lasting up The post MGFA Session 2025: Single dose of KYV-101 eases gMG symptoms appeared first on Myasthenia Gravis News.
- MGFA Session 2025: Telitacicept eases gMG symptoms long term
by Lila Levinson, PhD on November 4, 2025 at 3:30 pmNearly one year of treatment with Remegen’s telitacicept in a clinical trial in China led to substantial and sustained reductions in symptom severity among adults with generalized myasthenia gravis (gMG). The post MGFA Session 2025: Telitacicept eases gMG symptoms long term appeared first on Myasthenia Gravis News.
- MGFA Session 2025: Imaavy eases gMG in teens for up to 1.5 years
by Lindsey Shapiro, PhD on November 3, 2025 at 2:30 pmTreatment with Imaavy (nipocalimab-aahu) has led to sustained disease control for up to 1.5 years among adolescents with generalized myasthenia gravis (gMG), according to data from the long-term extension (LTE) The post MGFA Session 2025: Imaavy eases gMG in teens for up to 1.5 years appeared first on Myasthenia Gravis News.
** MGFA Disclaimer – Please read
Myasthenia Gravis Foundation of America (MGFA) and Bionews, Inc. (specifically Myasthenia Gravis News) have entered into a limited agreement that allows for the MGFA to post a link to Myasthenia Gravis News on the myasthenia.org website. Myasthenia Gravis News is a digital platform intended to provide the myasthenia gravis (MG) community with the most recent news and information on MG, as well as first-hand community perspectives from patient and caregiver columnists. All articles on Myasthenia Gravis News are original content produced by in-house writers and editors. Occasionally, Bionews seeks the opinion of outside experts for interviews and Q&As.
The publishing team at Myasthenia Gravis News is made up of science writers and editors, most of whom have PhDs in the life sciences; veteran journalists; and columnists who are members of the MG community. Together, they attempt to ensure that all content published on Myasthenia Gravis News is relevant, accurate, informative, relatable, and easy to understand.
Each piece of content is carefully selected and written by Bionews writers with the MG community in mind. Sources for news stories and resource pages include peer-reviewed studies, press releases, announcements, interviews, webinars, and conference sessions, among others. All articles go through a stringent fact-checking and editing procedure as part of Bionews’ process to ensure they are accurate, objective, comprehensive, and well-explained.
Columns are written by MG patients and caregivers who provide an intimate look at what it’s like to live with the disease. While columns are largely opinion and perspective pieces, each one still goes through a comprehensive editing and fact-checking process by Bionews editors to ensure clarity, accuracy, and fairness.
Myasthenia Gravis News’ site is strictly a news and information website about the disease. It DOES NOT provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The information provided is for educational purposes only and does not substitute for professional medical advice.
The content reflects the unique experiences of the authors and is not necessarily the opinion, views, or recommendations of the MGFA. Medical advisors and clinicians associated with or partnering with the MGFA do not peer review articles and information posted on the Myasthenia Gravis News platform or website. MGFA should not be liable for any information, opinions, articles, advice, guidance, or details posted on the Myasthenia Gravis News site. MGFA has posted this platform as a service to the MG community. Please consult with your doctor and healthcare professionals for specific recommendations and advice pertaining to your healthcare/treatment.